Immuron travelan® sales continued strong growth

Sales highlights: global fytd mar 2024 aud$3.6 million up 154% on (prior comparative period) pcp mar 2024 quarter aud$1.3 million up 51% on pcp and 75% on last quarter     australia fytd mar 2024 aud$2.8 million up 234% on pcp mar 2024 quarter aud$0.9 million up 66% on pcp and 99% on last quarter     usa fytd mar 2024 aud$0.8 million up 35% on pcp mar 2024 quarter aud$0.3 million up 7% on pcp and 18% on last quarter sales commenced on walmart.com melbourne, australia, april 10, 2024 (globe newswire) -- immuron limited (asx: imc; nasdaq: imrn), an australian based and globally integrated biopharmaceutical company is pleased to announce record sales (unaudited) of travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (gi) tract. australia sales of travelan® increased 250% to aud $2.7 million fytd mar 2024 compared to aud $0.8 million fytd mar 2023.
IMRN Ratings Summary
IMRN Quant Ranking